Literature DB >> 18432594

Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation.

D Kindgen-Milles1, J Amman, W Kleinekofort, S Morgera.   

Abstract

The use of citrate as an anticoagulant in continuous renal replacement therapy is an effective method to achieve regional anticoagulation of the extracorporeal blood circuit and to avoid systemic anticoagulation. This allows bleeding complications to be reduced and filter life time to be prolonged. However, citrate enters the systemic circulation and is metabolized in the liver to bicarbonate, causing metabolic alkalosis in some patients. In this case report, we discuss therapeutic interventions to control the acid-base status and to restore normal pH during continuous citrate hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18432594     DOI: 10.1177/039139880803100414

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  4 in total

1.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

2.  Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit.

Authors:  Andrew Davenport; Ashita Tolwani
Journal:  NDT Plus       Date:  2009-09-25

3.  Low bicarbonate replacement fluid normalizes metabolic alkalosis during continuous veno-venous hemofiltration with regional citrate anticoagulation.

Authors:  Paul Köglberger; Sebastian J Klein; Georg Franz Lehner; Romuald Bellmann; Andreas Peer; Daniel Schwärzler; Michael Joannidis
Journal:  Ann Intensive Care       Date:  2021-04-23       Impact factor: 6.925

4.  Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Authors:  Torsten Slowinski; Stanislao Morgera; Michael Joannidis; Thomas Henneberg; Reto Stocker; Elin Helset; Kirsti Andersson; Markus Wehner; Justyna Kozik-Jaromin; Sarah Brett; Julia Hasslacher; John F Stover; Harm Peters; Hans-H Neumayer; Detlef Kindgen-Milles
Journal:  Crit Care       Date:  2015-09-29       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.